Table 3.
Antibiotic susceptibility profiles of strains used in the study.
| Antibiotics | MDR Clinical Strains | ||||||
|---|---|---|---|---|---|---|---|
| A. baumannii ATCC 19606 | A. baumannii Col S | A. baumannii Col R1 | A. baumannii Col R2 | A. baumannii Col R3 | K. pneumoniae KPC 1 | K. pneumoniae KPC 2 | |
| PIP/TAZO | NT | NT | NT | NT | NT | >16 (R) | >16 (R) |
| MEM | 1 (S) | >8 (R) | >8 (R) | >8 (R) | 8 (S) | >8 (R) | >8 (R) |
| IMP | ≤1 (S) | >8 (R) | >8 (R) | >8 (R) | >8 (R) | >8 (R) | >8 (R) |
| ERT | NT | NT | NT | NT | NT | >1 (R) | >1 (R) |
| CAZ | NT | NT | NT | NT | NT | >8 (R) | >8 (R) |
| CTX | NT | NT | NT | NT | NT | >16 (R) | >16 (R) |
| CEFE | NT | NT | NT | NT | NT | >8 (R) | >8 (R) |
| GENTA | >4 (R) | >4 (R) | >4 (R) | >4 (R) | >4 (R) | 4 (R) | 4 (R) |
| AMIKA | NT | NT | >16 (R) | NT | NT | >16 (R) | >16 (R) |
| FOSFO | NT | NT | NT | NT | NT | >32 (R) | >32 (R) |
| SXT | >4/76 (R) | >4/76 (R) | >4/76 (R) | >4/76 (R) | >4/76 (R) | >4/76 (R) | ≤2/38 (S) |
| CIPRO | 1(S) | >1 (R) | >1 (R) | >1 (R) | >1 (R) | >1 (R) | NT |
| LEVO | ≤0.5 (S) | >1 (R) | >1 (R) | >1 (R) | >1 (R) | >1 (R) | >1 (R) |
| CAZ/AVI | NT | NT | NT | NT | NT | ≤2 (S) | ≤2 (S) |
| COL | ≤2 (S) | ≤2 (S) | >4 (R) | >4 (R) | >4 (R) | >4 (R) | >4 (R) |
MIC values (μg/mL); NT: not tested; PIP/TAZO: Piperacillin/tazobactam; MEM: Meropenem; IMP: Imipenem; ERT: Ertapenem; CAZ: Ceftazidime; CTX: Cefotaxime; CEFE: Cefepime; GENTA: Gentamicin; AMIKA: Amikacin; FOSFO: Fosfomycin; SXT: Trimethoprim/Sulfamethoxazole; CIPRO: Ciprofloxacin; LEVO: Levofloxacin; CAZ/AVI: Ceftazidime-Avibactam; COL: colistin.